No Data
No Data
Why Investors Shouldn't Be Surprised By Alphamab Oncology's (HKG:9966) 26% Share Price Surge
Alphamab Oncology Presents Clinical Study Results for Tumor Treatment at Houston Cancer Meet
Selected for LBA! The latest breakthrough clinical research results of Corning Jerry HER2 dual anti-ADC subcutaneous injection compound preparation JSKN033 will be presented at the 2024 SITC Annual Meeting.
On November 11, 2024 in Suzhou /PRNewswire/ -- Conic Jerry Biopharmaceutical (stock code: 9966.HK) announced that the first human clinical study results of the high-concentration subcutaneous injection compound preparation JSKN033 of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 inhibitor were selected for the latest breakthrough abstracts at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in 2024.
Alphamab Oncology (HKG:9966) Has Debt But No Earnings; Should You Worry?
Hong Kong stock market anomaly | Some pharmaceutical stocks rise, medical insurance negotiations support innovative drugs. Institutions point out that the sector still has further room for recovery.
Some pharmaceutical stocks rose, as of the deadline, SciClone Pharmaceuticals-B (02171) rose by 33.68% to HK$8.97; Concord Jingrui Pharmaceuticals-B (09966) rose by 10.34% to HK$4.27; LuPu Biotech-B (02157) rose by 7.87% to HK$3.29.
Alphamab Oncology Receives Waivers for Company Secretary From Hong Kong Bourse
No Data
No Data